Business Description
NurExone Biologic Inc
NAICS : 325412
SIC : 3741
ISIN : CA67059R1091
Description
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 81.38 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | -20.15 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.32 | |||||
| 9-Day RSI | 57.65 | |||||
| 14-Day RSI | 56.64 | |||||
| 6-1 Month Momentum % | 8.16 | |||||
| 12-1 Month Momentum % | 196.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.49 | |||||
| Quick Ratio | 6.49 | |||||
| Cash Ratio | 5.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -3.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -210.63 | |||||
| ROA % | -144.84 | |||||
| ROIC % | -611.17 | |||||
| ROC (Joel Greenblatt) % | -1010.97 | |||||
| ROCE % | -195.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 11.43 | |||||
| Price-to-Tangible-Book | 10.6 | |||||
| EV-to-EBIT | -8.3 | |||||
| EV-to-EBITDA | -8.4 | |||||
| EV-to-FCF | -7.86 | |||||
| Price-to-Net-Current-Asset-Value | 17.67 | |||||
| Price-to-Net-Cash | 17.67 | |||||
| Earnings Yield (Greenblatt) % | -12.05 | |||||
| FCF Yield % | -11.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NurExone Biologic Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.067 | ||
| Beta | 0 | ||
| Volatility % | 103.78 | ||
| 14-Day RSI | 56.64 | ||
| 14-Day ATR (€) | 0.034011 | ||
| 20-Day SMA (€) | 0.50375 | ||
| 12-1 Month Momentum % | 196.09 | ||
| 52-Week Range (€) | 0.163 - 0.92 | ||
| Shares Outstanding (Mil) | 70.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NurExone Biologic Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NurExone Biologic Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NurExone Biologic Inc Frequently Asked Questions
What is NurExone Biologic Inc(FRA:J90)'s stock price today?
The current price of FRA:J90 is €0.53. The 52 week high of FRA:J90 is €0.92 and 52 week low is €0.16.
When is next earnings date of NurExone Biologic Inc(FRA:J90)?
The next earnings date of NurExone Biologic Inc(FRA:J90) is .
Does NurExone Biologic Inc(FRA:J90) pay dividends? If so, how much?
NurExone Biologic Inc(FRA:J90) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers